Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Meredith Wagner

Dermatology Chattanooga, TN Medical Doctor

NPI 1316380694 CMS profile 3647836

1110 Market St Ste 210, Chattanooga, TN 37402

Open in the dashboard

General payments

$4,688

257 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meredith Wagner of Chattanooga, TN is reported in the CMS Open Payments database as having received $4,688 across 257 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27 1
2023 General $863 43
2022 General $1,532 84
2021 General $860 59
2020 General $541 34
2019 General $865 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meredith Wagner
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Meredith Wagner were reported at $27. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Meredith Wagner Dermatology median Middle half National median
2019 $865 $454 $129–$1,240 $163
2020 $541 $235 $81–$756 $114
2021 $860 $377 $108–$1,108 $132
2022 $1,532 $514 $143–$1,391 $149
2023 $863 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $27 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,044 74 payments
  2. Pfizer Inc. $486 27 payments
  3. Novartis Pharmaceuticals Corporation $425 22 payments
  4. Janssen Biotech, Inc. $389 24 payments
  5. Genzyme Corporation $383 18 payments
  6. Lilly USA, LLC $309 19 payments
  7. E.R. Squibb & Sons, L.L.C. $249 9 payments
  8. Sun Pharmaceutical Industries Inc. $232 7 payments
  9. PruGen, Inc. Pharmaceuticals $194 2 payments
  10. Amgen Inc. $126 5 payments
  11. Other $852 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,688 257 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $705 49 payments
  2. EUCRISA $486 27 payments
  3. DUPIXENT $450 20 payments
  4. TALTZ $309 19 payments
  5. TREMFYA $270 18 payments
  6. SOTYKTU $236 8 payments
  7. HUMIRA $215 17 payments
  8. COSENTYX $210 12 payments
  9. RINVOQ $165 11 payments
  10. CIBINQO $163 11 payments
  11. Other $2,274 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

402

Median for Dermatology: 534

Drug cost

$122,817

Median for Dermatology: $67,151

Branded share of claims

7.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 17 $64,667
Dupixent Pen Dupilumab Brand 13 $49,133
Fluocinonide Generic 35 $1,267
Ketoconazole Generic 64 $1,194
Clobetasol Propionate Generic 19 $1,144
Clindamycin Phosphate Generic 24 $1,008
Fluorouracil Generic 13 $746
Triamcinolone Acetonide Generic 49 $741
Tacrolimus Generic 12 $740
Tretinoin Generic 16 $625

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$43,894

Medicare's payments for the services billed

Medicare patients

243

Average age 73

Services billed

1,113

136 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 39%
Ischemic heart disease 34%
Diabetes 25%
Chronic kidney disease 23%
COPD 21%
Cancer 21%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record